Testicular Cancer Awareness Month: Improving Detection, Management, and Survivorship [Video]

In honor of Testicular Cancer Awareness Month, Oncology Data Advisor Fellows Forum members Samuel Kareff, MD, MPH, Waqas Haque, MD, MPH, and Matthew Hadfield, DO, sat down to discuss improving early detection, minimizing toxicities of treatment, and optimizing long-term survivorship, particularly for adolescent and young adult (AYA) survivors of testicular cancer.

“Testicular cancer is a rare tumor type, relatively speaking, as it relates to incidence and prevalence in the United States, but it’s certainly something that’s worth taking the extra moment to educate yourself on so you can do the best for your patients.” – Samuel Kareff, MD, MPH

“This is the most common but also the most treatable form of cancer in adolescent and young adult males, and because of the higher survivorship rate, a lot of testicular cancer patients spend most of their life as survivors, which we can’t always talk about for other forms of cancer.” – Waqas Haque, MD, MPH

“Someone in their early twenties getting cancer is a horrible, horrible thing, so involving as many support services as you can on the care team to help with those conversations and help them adjust to their new diagnosis is critical.” – Matthew Hadfield, DO

About the Speakers

Samuel Kareff, MD, MPH, is a Medical Oncologist and a Hematology-Oncology Fellow at the University of Miami’s Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital in Florida. He has special research interests in health advocacy, public policy, and the development of cancer therapies.

Waqas Haque, MD, MPH, is a third-year Internal Medicine Resident at New York University (NYU) in a Clinical Investigator Track. He recently matched to the University of Chicago for fellowship, which he will be beginning later in 2024. As a Clinical Investigator Track Resident, Dr. Haque has balanced his patient care work with a variety of research projects. During his fellowship training at University of Chicago, he plans to further his work in innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation.

Matthew Hadfield, DO, is a Hematology/Oncology Fellow at Brown University/Legoretta Cancer Center in Providence, Rhode Island. Prior to fellowship, he completed his Internal Medicine Residency at the University of Connecticut in 2021. Dr. Hadfield’s research focuses on melanoma and early-phase clinical trials. To date, he has published numerous peer-reviewed articles and studies, and he has presented his research at multiple national and international meetings. His main areas of interest include early-phase drug development, novel immunotherapeutic combinations to overcome therapeutic resistance, and predictive biomarkers for immunotherapy toxicities.